S
Susan Buchbinder
Researcher at University of California, San Francisco
Publications - 339
Citations - 44394
Susan Buchbinder is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Men who have sex with men & Acquired immunodeficiency syndrome (AIDS). The author has an hindex of 98, co-authored 329 publications receiving 40954 citations.
Papers
More filters
Journal ArticleDOI
Preexposure Chemoprophylaxis for HIV Prevention in Men Who Have Sex with Men
Robert M. Grant,Javier R. Lama,Peter L. Anderson,Vanessa McMahan,Albert Y. Liu,Lorena Vargas,Pedro Goicochea,Martin Casapia,Juan Vicente Guanira-Carranza,Maria Esther Ramirez-Cardich,Orlando Montoya-Herrera,Telmo Fernandez,Valdilea G. Veloso,Susan Buchbinder,Suwat Chariyalertsak,Mauro Schechter,Linda-Gail Bekker,Kenneth H. Mayer,Esper G. Kallas,K. Rivet Amico,Kathleen Mulligan,Lane R. Bushman,Robert J. Hance,Carmela Ganoza,Patricia Defechereux,Brian S. Postle,Furong Wang,J. Jeff McConnell,Jia-Hua Zheng,Jeanny Lee,James F. Rooney,Howard S. Jaffe,Ana Martinez,David N. Burns,David V. Glidden +34 more
TL;DR: Oral FTC-TDF provided protection against the acquisition of HIV infection among the subjects and Detectable blood levels strongly correlated with the prophylactic effect.
Journal ArticleDOI
Genetic Restriction of HIV-1 Infection and Progression to AIDS by a Deletion Allele of the CKR5 Structural Gene
Michael Dean,Mary Carrington,Cheryl A. Winkler,Gavin A. Huttley,Michael W. Smith,Rando Allikmets,James J. Goedert,Susan Buchbinder,Eric Vittinghoff,Edward D. Gomperts,Sharyne Donfield,David Vlahov,Richard A. Kaslow,Alfred J. Saah,Charles R. Rinaldo,Roger Detels,Stephen J. O'Brien +16 more
TL;DR: The CKR5Δ32 deletion may act as a recessive restriction gene against HIV-1 infection and may exert a dominant phenotype of delaying progression to AIDS among infected individuals.
Journal ArticleDOI
Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial.
Susan Buchbinder,Devan V. Mehrotra,Ann Duerr,Daniel W. Fitzgerald,Robin Mogg,David Li,Peter B. Gilbert,Javier R. Lama,Michael Marmor,Carlos del Rio,M. Juliana McElrath,Danilo R. Casimiro,Keith Gottesdiener,Chodakewitz Jeffrey A,Lawrence Corey,Michael N. Robertson +15 more
TL;DR: This cell-mediated immunity vaccine did not prevent HIV-1 infection or reduce early viral level and Mechanisms for insufficient efficacy of the vaccine and the increased HIV- 1 infection rates in subgroups of vaccine recipients are being explored.
Journal ArticleDOI
HLA and HIV-1: heterozygote advantage and B*35-Cw*04 disadvantage.
Mary Carrington,George W. Nelson,Maureen P. Martin,Teri Kissner,David Vlahov,James J. Goedert,Richard A. Kaslow,Susan Buchbinder,Keith Hoots,Stephen J. O'Brien +9 more
TL;DR: The extended survival of 28 to 40 percent of HIV-1-infected Caucasian patients who avoided AIDS for ten or more years can be attributed to their being fully heterozygous at HLA class I loci, to their lacking the AIDS-associated alleles B*35 and Cw*04, or to both.
Journal ArticleDOI
Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS
Maureen P. Martin,Xiaojiang Gao,Jeong Hee Lee,George W. Nelson,Roger Detels,James J. Goedert,Susan Buchbinder,Keith Hoots,David Vlahov,John Trowsdale,Michael A Wilson,Michael A Wilson,Stephen J. O'Brien,Mary Carrington +13 more
TL;DR: The strongest synergistic effect of these loci was on progression to depletion of CD4+ T cells, which suggests that a protective response of NK cells involving KIR3DS1 and its HLA class I ligands begins soon after HIV-1 infection.